I am a neurologist and clinician-scientist at Yamaguchi University, Japan, where I lead translational research on blood–brain barrier (BBB) dysfunction in neuroinflammatory and neurodegenerative disorders. My team develops patient-derived iPSC-based BBB models to uncover molecular mechanisms and therapeutic targets underlying disorders such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and hereditary cerebral small vessel diseases.
As the organizer of CVB2029 in Japan, I am committed to strengthening the international BBB research network by fostering active participation from Asian researchers and enhancing diversity and inclusiveness within the IBBS community. In particular, I aim to promote collaboration among investigators working with human tissue, in vivo human imaging, and stem cell–based barrier models.
As a relatively early-career investigator, I also aspire to serve as a bridge between junior scientists and senior principal investigators, facilitating intergenerational dialogue and ensuring that the voices of emerging researchers are represented in the future development of IBBS.
